What the "peptide purity" percentage actually measures
The number on a COA is an area-under-curve (AUC) figure from reversed-phase high-performance liquid chromatography. The instrument passes the dissolved sample through a stationary-phase column, detects UV absorption at 214 nm as each component elutes, and expresses the target peptide's peak area as a fraction of all detected peak area. If the target peak accounts for 99% of the UV-absorbing signal, the COA reads ">99%."
That figure has three gaps worth knowing. First, it excludes material that does not absorb strongly at 214 nm: water, inorganic salts, and residual trifluoroacetic acid (TFA) from the synthesis and purification process. Second, it cannot distinguish the target peptide from a structurally similar variant that co-elutes at the same retention time. Third, it is a peak-area ratio rather than a mass assay, so it does not report how many milligrams of active peptide are actually in the vial.
A 2018 study in Analytical and Bioanalytical Chemistry (Melanson et al., angiotensin II certified reference material) demonstrated the gap directly. The researchers combined quantitative NMR and LC-MS/MS amino acid analysis to assign purity to the same material. They found that single-method HPLC values diverge from multi-method results because HPLC omits counter-ions and moisture-derived mass from the denominator.
How RP-HPLC separates and scores the sample
Most peptide suppliers run a C18 reversed-phase column, though C4 and C8 stationary phases are common for larger or more hydrophobic sequences. Mant et al. (Methods in Molecular Biology, 2007) describe reversed-phase liquid chromatography as the dominant technique for synthetic peptide purity analysis, noting its resolving power for amphipathic sequences across a wide molecular weight range.
The mobile phase runs a gradient from high aqueous to high organic solvent, typically acetonitrile with 0.1% TFA. Hydrophilic components elute first; the target peptide elutes at its characteristic retention time. Some laboratories add a second UV channel at 280 nm to detect peptides containing tyrosine or tryptophan residues.
The chromatogram is a time-series plot with UV absorption on the Y axis and elution time on the X axis. Each peak represents a compound coming off the column at that moment. The target peak is the dominant feature in a high-purity batch, and smaller satellite peaks flanking it represent the impurities that RP-HPLC separates and counts. The most common synthesis-related impurities include deletion sequences (one or more amino acids absent from the chain), truncated chains from incomplete elongation, oxidation products at methionine or cysteine residues, and disulfide-bonded dimers formed during lyophilization.
What mass spectrometry confirms on the COA
HPLC purity answers how much of what is detected is the target peak. Mass spectrometry answers whether the target peak is the correct compound.
A COA MS readout reports the observed mass-to-charge ratio (m/z) measured against the theoretical m/z calculated from the peptide's amino acid sequence and molecular formula. A match within 0.1 Da for low-resolution instruments, or within 5 parts per million for high-resolution instruments, confirms molecular identity. This does not confirm amino acid order. Full sequence verification requires MS/MS fragmentation data, which some COAs include as a supplementary spectrum.
Zeng et al. (AAPS Journal, 2015; FDA, n=3 model peptide drugs: salmon calcitonin, bivalirudin, exenatide) showed that LC-high-resolution MS can detect impurities present at less than 0.1% of the active peptide concentration, with intra-assay precision below 10% relative standard deviation and method accuracy above 85%. A batch showing ">99%" HPLC purity may still carry trace impurities that high-resolution MS resolves but the HPLC chromatogram cannot separate as distinct peaks.
A COA that contains only HPLC data is a weaker analytical package than one pairing HPLC purity with MS identity confirmation. When reviewing a supplier's documentation, check that both are present before committing a batch to a quantitative experiment.
Other COA fields that matter for reproducibility
Beyond the purity percentage and MS identity check, a research-grade COA contains several fields that directly affect experimental reproducibility. The batch or lot number links to the full synthesis and QC record; if a study result is later challenged, the lot number is the traceable starting point. The observed molecular weight, listed alongside the theoretical value, should match to within the instrument's stated tolerance.
Water content is reported as a percentage and typically runs 5-15% in lyophilized peptides. A COA that omits this figure makes accurate concentration calculations impossible, because the vial's mass includes moisture that contributes no biological activity. The calculation converting vial mass to working concentration depends on both the HPLC purity and the water content figures. The peptide reconstitution guide covers how each factor affects the final molarity when preparing stock solutions.
Some COAs specify residual TFA content as a separate field. TFA does not absorb strongly at 214 nm, so it does not reduce the HPLC purity percentage, but it adds mass to the vial and can acidify cell culture media at higher loads. For in-vitro cell work, also ask whether the batch has been tested for endotoxins. Lipopolysaccharide contamination confounds immunological assays at concentrations entirely independent of peptide purity. McCarthy et al. (Pharmaceutical Research, 2023; multi-lab peptide reference standard program) note that identity, purity, and strength each require different analytical methods: HPLC for purity, MS for identity, and amino acid analysis or qNMR for the actual amount of active peptide per vial. No single COA figure covers all three.
Matching purity grade to research design
Purity requirements track assay sensitivity rather than compound cost. The threshold where impurity level starts affecting results depends on the concentration at which the target peptide acts and how sensitive the endpoint is to off-target signal.
For receptor binding assays, structure-activity relationship (SAR) studies, or any quantitative work where a 10-nanomolar concentration difference matters, 98% purity is the minimum working standard. At 95% purity, a 1 mg sample contains approximately 50 micrograms of unidentified material. In a nanomolar-range binding assay, that fraction is large enough to produce measurable off-target signal. For initial in-vivo rodent screening at coarser endpoints, 95% is often adequate for a first pass; researchers typically upgrade to 98% or higher for dose-response characterization.
Clinical-grade peptide material used in investigational new drug applications typically requires 99% or above with a full impurity profile that identifies and quantifies each satellite peak. Research-use-only material is not held to that standard, but the underlying logic is the same: each percentage point of impurity is a fraction of vial mass with unknown biological activity in sensitive assays.
Before preparing working solutions, calculate the actual peptide mass available from the purity and water content figures on the COA. The dosing calculator handles this arithmetic for all compounds in the catalog and adjusts for reconstitution volume and molecular weight.
Handling COA-verified peptides in tropical research settings
A COA certifies purity at manufacture. Degradation begins the moment the peptide encounters heat, moisture, or oxidizing conditions during transit and storage, and those conditions are harder to control in Indonesia than in a temperate-climate facility.
Two degradation pathways accelerate in tropical conditions. Hydrolysis of the peptide bond is driven by moisture and temperature; a peptide exposed to four hours at 30 degrees Celsius on a loading dock accumulates more cumulative damage than one held at -20 degrees Celsius for a year. Oxidation at methionine, cysteine, and tryptophan residues is catalyzed by dissolved oxygen, light, and trace metal contaminants, all of which are more prevalent in uncontrolled environments than in a purpose-built cold room. Both pathways produce impurities absent from the manufacturer's COA, because the COA was issued before those conditions occurred.
The practical guidance for researchers in Bali, Jakarta, and Surabaya is covered in the lyophilized peptide storage guide: receive shipments with cold-chain packaging intact, transfer directly to the target storage temperature, and keep lyophilized powder sealed and desiccated until reconstitution. Cross-check the lot number on the COA against the vial label before opening each batch to confirm the documented material is what is being used. Zurich Biotech ships all compounds with the manufacturer's original COA and uses insulated cold-chain packaging for all deliveries across Indonesia.